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Abstract Knowledge of the uncertainty in model param-
eters is essential for decision-making in drug development.
Contrarily to other aspects of nonlinear mixed effects
models (NLMEM), scrutiny towards assumptions around
parameter uncertainty is low, and no diagnostic exists to
judge whether the estimated uncertainty is appropriate.
This work aims at introducing a diagnostic capable of
assessing the appropriateness of a given parameter uncer-
tainty distribution. The new diagnostic was applied to case
bootstrap examples in order to investigate for which dataset
sizes case bootstrap is appropriate for NLMEM. The pro-
posed diagnostic is a plot comparing the distribution of
differences in objective function values (dOFV) of the
proposed uncertainty distribution to a theoretical Chi
square distribution with degrees of freedom equal to the
number of estimated model parameters. The uncertainty
distribution was deemed appropriate if its dOFV distribu-
tion was overlaid with or below the theoretical distribution.
The diagnostic was applied to the bootstrap of two real data
and two simulated data examples, featuring pharmacoki-
netic and pharmacodynamic models and datasets of 20–200
individuals with between 2 and 5 observations on aver-
age per individual. In the real data examples, the diagnostic
indicated that case bootstrap was unsuitable for NLMEM
analyses with around 70 individuals. A measure of
parameter-specific ‘‘effective’’ sample size was proposed
as a potentially better indicator of bootstrap adequacy than
overall sample size. In the simulation examples, bootstrap
confidence intervals were shown to underestimate inter-
individual variability at low sample sizes. The proposed
diagnostic proved a relevant tool for assessing the appro-
priateness of a given parameter uncertainty distribution and
as such it should be routinely used.
Keywords Parameter uncertainty distributions 
Bootstrap  Model diagnostics  Nonlinear mixed-effects
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Introduction
The utilization of non-linear mixed effects models
(NLMEM) in drug discovery and development has
increased in the last decades. In a recent white paper aimed
at both decision makers and practitioners, the importance
and implementation of Model-Informed Drug Discovery
and Development (MID3) was outlined [1]. As exemplified
and stressed in this consensus paper, understanding and
quantifying model uncertainty has a central role in model-
informed decision-making. Model uncertainty includes
qualitative aspects, mainly the adequacy of the assumptions
underpinning the model(s), but also quantitative aspects,
mainly the joint uncertainty of the estimated parameters of
the model(s). A number of methods to quantify parameter
uncertainty are available. The most commonly used
method is to derive standard errors around the parameters
from the asymptotic covariance matrix, which is provided
as a standard output of most software. A drawback of this
uncertainty estimate is that parameter confidence intervals
(CI) as well as simulation and prediction uncertainties
require additional assumptions about the shape of the
uncertainty distribution. Most often a multivariate normal
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distribution is used, which provides CI that are symmetric
around the point estimate. To relax the assumption of
symmetric CI, likelihood profiling is sometimes used [2].
However, while applicable to the uncertainty of each
parameter separately, likelihood profiling does not allow
the use of the combined uncertainty around all model
parameters for simulations or predictions. The most fre-
quently used method for generation of parameter uncer-
tainty without symmetry constraint is the nonparametric, or
‘‘case’’, bootstrap [3]. Case bootstrap of independent data
consists of estimating model parameters on a number of
datasets obtained by resampling with replacement ‘‘pairs’’
of dependent and independent variables. It is often con-
sidered as the gold standard for estimating parameter
uncertainty. Occasionally, other bootstrap variants are
used, for example nonparametric and parametric residual
bootstrap [4]. Sampling Importance Resampling (SIR) has
recently been proposed for improving the estimation of
parameter uncertainty in NLMEM [5]. Lastly, for models
estimated by Bayesian methods, the full posterior param-
eter distribution is typically used to represent parameter
uncertainty [6].
Case bootstrap is not devoid of limitations. It is for
example not suitable for ‘‘small’’ or highly designed
datasets for which stratification is impossible (such as
model-based meta-analysis [7]) or leads to too small sub-
groups. Using bootstrap in these cases has a high risk of
leading to biased uncertainty estimates. Models relying on
frequentist parameter priors for parameter estimation [8]
are also not suited for bootstrap, as the uncertainty of
parameters featuring highly informative priors and low
information in the data will be underestimated. In the
particular context of NLMEM, what represents a too small
dataset is not well known. In any case, a minimum dataset
size would need to take model complexity into account. As
models typically grow in complexity with increasing
dataset sizes in order to maximize the amount of infor-
mation extracted from the data, one might suggest that
datasets are often small with regards to the developed
models. In addition, typically each individual, or ‘‘case’’,
only provides incomplete information about the parameters
that are to be estimated. Likewise, individuals contain
different amounts of information and are thus not fully
exchangeable. Reasons for this may be different designs
(doses, number or timing of observations) and different
covariate values, but even with the same design and
covariate values, the information about a parameter will be
linked to the individual’s value for that parameter and thus
differ between ‘‘cases’’.
The appropriateness of the point estimates of model
parameters is typically scrutinized using a variety of
graphical diagnostics based on predictions, residuals and
simulations. The choice of models and estimation methods
in an analysis is typically driven by such diagnostics. The
same is not true for estimates of parameter uncertainty.
Typically, the appropriateness of the uncertainty estimates
is not investigated. Instead, the choice of method for the
estimation of parameter uncertainty is usually based on the
expectation of performance combined with practical
aspects (runtime, model stability, etc.). In the present work,
we propose a diagnostic for estimates of parameter
uncertainty. The intention for its use is mainly to allow
assessment of the appropriateness of estimated parameter
uncertainty in relation to the underlying real dataset, but its
properties will also be explored in relation to simulated
data. For illustration of the parameter uncertainty diag-




A NLMEM is a statistical model which typically describes
how an endpoint changes over time in different individuals.
It is usually defined by a set of differential equations and
comprises Npar population parameters. The vector of pop-
ulation parameters P comprises both fixed and random
effects, which can be combined to obtain vectors of indi-
vidual parameters Pi. Estimates of the population param-
eters, P^, can be obtained from a dataset D containing a total
number of observations Nobs arising from Nid individuals
by minimization of the objective function value (OFV),
which is equal (up to a constant) to minus two times the
log-likelihood of the data given the parameters.
Bootstrap setup
Uncertainty in the population parameters estimated on
dataset D can be obtained via bootstrap. Bootstrap results
considered in this work consisted of Nboot = 1000 param-
eter vectors obtained by fitting the model, i.e. estimating
the population parameters, in Nboot bootstrapped datasets.
The bootstrapped datasets were obtained from the original
data using case bootstrap, where the full data of one indi-
vidual was resampled with replacement to obtain boot-
strapped datasets containing the same number of
individuals as the original dataset. Some individuals are
thus present multiple times within a bootstrapped dataset,
in which case they are treated as independent individuals;
oppositely, some individuals are not present at all. Strati-
fication, i.e. the classification of individuals into subgroups
prior to resampling, was not used here. Model fitting of the
bootstrapped datasets was performed the same way as with
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the original dataset, with initial parameter estimates set to
P^. Nonparametric percentiles-based CI were derived for
each parameter from all available bootstrap parameter
vectors, regardless of their termination status (i.e. runs with
and without successful minimization were used to compute
bootstrap CI).
dOFV distribution diagnostic
A diagnostic was developed to assess whether the uncer-
tainty of NLMEM parameter estimates, as obtained by the
bootstrap procedure described above, was appropriate.
The new diagnostic is based on the comparison of the
distribution of the differences in OFV (dOFV) for a pro-
posed uncertainty estimate, in this case the bootstrap, to a
theoretical dOFV distribution. The two dOFV distributions
are generated according to the following procedure:
Bootstrap dOFV distribution
The bootstrap dOFV distribution is derived from the results
of the bootstrap of the original dataset, which consist of
Nboot parameter vectors. Each one of the Nboot parameter
vectors has been estimated on a different bootstrapped
dataset. Each of these vectors is then used to evaluate the
likelihood of the original data given this particular vector.
For one vector, this means that the OFV of the original data
is calculated by fixing all model parameters to their value
in the vector (in the NONMEM [13] software, this corre-
sponds to using the bootstrap parameter vector as initial
estimates in $THETA, $OMEGA and $SIGMA and setting
MAXEVAL = 0 in $EST). This is done for each of the
Nboot vectors, leading to Nboot OFVs. Next, the final OFV
of the original model, obtained with the final parameter
estimates on the original data (using MAXEVAL = 9999
in $EST), is subtracted from each of the Nboot OFVs. One
thus obtains Nboot dOFVs (Eq. 1).
dOFVbootN ¼ OFVP^bootN ;D  OFVP^D;D ð1Þ
where dOFVbootN is the N-th bootstrap dOFV. The first
index of the OFV corresponds to the parameter vector used,
and the second to the dataset the parameter vector is esti-
mated (MAXEVAL = 9999 in NONMEM) or evaluated
(MAXEVAL = 0) on. P^bootN is the parameter vector esti-
mated on the N-th bootstrap dataset, and P^D is the
parameter vector estimated on the original dataset D.
Theoretical dOFV distribution
The second dOFV distribution, referred to as the theoretical
dOFV distribution, corresponds to a Chi square distribution
with degrees of freedom (df) equal to the number of esti-
mated model parameters Npar (Eq. 2).
dOFVtheoreticalN ¼ randomðv2NparÞ ð2Þ
where dOFVtheoreticalN is the N-th Chi square dOFV
obtained by random sampling from a Chi square distribu-
tion with Npar degrees of freedom.
The proposed diagnostic displays the quantile functions,
also known as the inverse cumulative distribution func-
tions, of the two dOFV distributions as illustrated in Fig. 1
(left panels—the bootstrap dOFV distribution is displayed
in blue and the theoretical dOFV distribution is displayed
in green). The quantile function specifies, for a given
probability in the probability distribution of a random
variable, the value at which the probability of the random
variable being less than or equal to this value is equal to the
given probability.
The principle behind the dOFV diagnostic is that if the
parameter vectors (obtained by performing a bootstrap for
example) were representative of the true uncertainty, their
dOFV distribution should follow a Chi square distribution
with a certain degrees of freedom. For unconstrained fixed
effects models, asymptotically the degrees of freedom of
the Chi square distribution should be equal to the number
of estimated parameters [9], and thus the bootstrap dOFV
distribution should overlay the theoretical dOFV distribu-
tion. However for NLMEM the exact degrees of freedom is
unknown. It could be equal or inferior to the number of
estimated parameters, notably due to the estimation of
random effects and other bounded parameters, which may
not account for full degrees of freedom. Other factors
influencing the dOFV distribution may be properties of the
estimation method (e.g. first or second-order approxima-
tions of the likelihood [10]) and the presence of model
misspecification. Because the true degrees of freedom is
unknown, the bootstrap dOFV distribution is not neces-
sarily expected to collapse to the theoretical dOFV distri-
bution when the uncertainty is appropriate. In the absence
of model misspecification, it is however expected to col-
lapse to the dOFV distribution obtained by stochastic
simulations and estimations (SSE, as described below). The
SSE dOFV distribution takes all model properties such as
the presence of random effects, boundaries, or the esti-
mation method into account, and thus represents the
expected dOFV distribution in the absence of model mis-
specification. The SSE dOFV distribution was computed
for the purpose of evaluating the proposed diagnostic, but it
is important to note that it is not part of the diagnostic in
practice due to its high computational burden. Instead, it is
computed here to evaluate whether the theoretical distri-
bution is a good enough surrogate for the SSE dOFV
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distribution for the investigated NLMEM. The SSE dOFV
distribution is obtained as follows:
SSE dOFV distribution
NSSE = 1000 datasets are simulated based on the given
model, with simulation parameters equal to the parameters
P^D estimated on the original data. For each simulated
dataset, two OFVs are computed: the OFV obtained by
estimating model parameters on the simulated dataset
(using the simulation parameters as initial estimates in
$THETA, $OMEGA and $SIGMA and setting MAX-
EVAL = 9999 in $EST), and the OFV obtained by eval-
uating the simulation parameters on the simulated dataset
(using the simulation parameters as initial estimates in
$THETA, $OMEGA and $SIGMA and setting MAX-
EVAL = 0 in $EST). A dOFV is then computed for each
dataset as the difference between the second and the first
OFV. One thus obtains NSSE SSE dOFVs (Eq. 3).
dOFVSSEN ¼ OFVP^SSEN ;SSEN  OFVP^D;SSEN ð3Þ
dOFVSSEN is the N-th SSE dOFV. The first index of the
OFV corresponds to the parameter vector used, and the
second to the dataset the parameter vector is estimated
(MAXEVAL = 9999 in NONMEM) or evaluated (MAX-
EVAL = 0) on. P^SSEN is the parameter vector estimated on
the N-th SSE dataset, and P^D is the parameter vector
estimated on the original dataset D.
The dOFV diagnostic assesses whether a given uncer-
tainty method is appropriate for a given dataset and model:
the uncertainty is considered appropriate if its dOFV dis-
tribution is at or below the theoretical distribution. In
addition, in this work we evaluated whether using the
theoretical dOFV distribution as a surrogate for the SSE
distribution was appropriate.
The adequacy of parameter uncertainty obtained by
bootstrap was evaluated based on two real data examples and
two simulation examples using the new dOFV distribution
diagnostic as well as other parameter distribution metrics.
For the real data examples, bootstrap dOFV distribu-
tions were assessed for (i) the original dataset, (ii) 10
datasets simulated with the final model and parameters
estimates using the original design, and (iii) 10 datasets
simulated with the final model and parameters estimates
using the original design but with an 8-fold increase in
the number of individuals. From these investigations both
the influence of dataset size (original size for i and ii,
increased size for iii) and model misspecification (po-
tential misspecification for i, no misspecification for ii and
iii) on bootstrap uncertainty adequacy could be assessed.
SSE and theoretical dOFV distributions were assessed for
all scenarios. Note that SSE dOFV distributions are
identical for i and ii, and that theoretical dOFV distri-
butions are identical for i, ii and iii.
For the simulation examples, bootstrap dOFV distribu-
tions were assessed for 100 simulated datasets for each
dataset size. SSE and theoretical dOFV distributions were
also assessed. The adequacy of parameter uncertainty was
further evaluated based on parameter CI, using parameter
CI obtained from the SSE (using 1000 samples) as the
reference. Coverage at the 90 % level was investigated for
each parameter by calculating the percentage of datasets
for which the 90 % CI included the true simulation value
for that parameter.
Fig. 1 dOFV distribution plots
for the two real data examples.
Left panels provide bootstrap
dOFV distributions for the real
data (blue), the theoretical
dOFV distribution (green) and
the SSE dOFV distribution
(pink). Middle and right panels
provide bootstrap dOFV
distributions for the simulated
datasets of equal and 8-fold
increased size (colors), as well
as the theoretical dOFV
distribution (black solid line).
Pheno. phenobarbital, Pef.
pefloxacin
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Investigated examples
Table 1 provides a summary of all investigated examples.
Phenobarbital
The phenobarbital dataset [11] consisted of 155 observa-
tions from 59 infants. Phenobarbital pharmacokinetics
(PK) were described by a one-compartment model with
multiple i.v. bolus administration and linear elimination.
The model included seven parameters: clearance (CL) and
volume of distribution (V) with inter-individual variability
(IIV), two covariate relationships (body weight on CL and
V), and additive residual unexplained variability (RUV).
Pefloxacin
The pefloxacin dataset [12] consisted of 337 observations
from 74 critically ill patients. The PK of pefloxacin was
described by a one-compartment model with multiple i.v.
bolus administration and linear elimination. The model
included ten parameters: CL and V with IIV and inter-occa-
sion variability (IOV) with correlations between the vari-
abilities of CL and V within a level, one covariate relationship
(creatinine clearance on CL), and proportional RUV.
Simulation 1
Data was simulated from a one-compartment PK model
with a single i.v. bolus administration of 100 and linear
elimination. The model included five parameters: CL and
V, equal to 1 and each displaying 30 % exponential IIV,
and an additive RUV on the log scale with a standard
deviation of 0.2. Three different dataset sizes were inves-
tigated: 20, 50 and 200 individuals, with four observations
each at 0.25, 0.5, 1 and 2 units post dose.
Simulation 2
Data was simulated from a pharmacodynamic (PD) dose–
response sigmoidal Emax model with baseline. The model
included seven parameters: a baseline (E0) of 10, an
additive maximum effect (EMAX) of 100 with a dose
leading to half the maximum effect (ED50) of 5, a Hill
factor (HILL) of 0.7, 30 % exponential IIV on E0 and
ED50, and a proportional RUV with a standard deviation of
10 %. Three different dataset sizes were investigated: 20,
50 and 200 individuals with four observations each at doses
of 0, 2.5, 5 and 15.
Software
Data simulation and analysis including parameter estima-
tion and evaluation was performed with NONMEM 7.2
[13] using PsN [14] as a modelling environment. The
dOFV diagnostic is fully automated for bootstrap using the
-dOFV option in PsN. Post-processing and graphical output
was performed in Rstudio 0.99.484 with R 3.2.1 [15].
Results
Real data examples
In the two investigated real data examples, theoretical and
SSE dOFV distributions were almost superimposed
whichever dataset size (Fig. 1). Bootstrap dOFV distribu-
tions showed different patterns for different dataset types
(observed vs. simulated data) and sizes.
For the original datasets (left panel of Fig. 1), bootstrap
dOFV distributions deviated clearly from the theoretical
dOFV distributions, with dOFVs consistently higher than
expected from the theoretical distribution. Estimated
degrees of freedom were 4–7 df (i.e. around 65 %) higher
Table 1 Summary of the investigated real data and simulation examples












Phenobarbital [11] 1-compartment PK model, multiple
i.v. doses, linear elimination
7 3 (0.43) 59, 472a 155, 1240a 2.6
Pefloxacin [12] 1-compartment PK model, multiple
i.v. doses, linear elimination
10 7 (0.70) 74, 592a 337, 2696a 4.6
Simulation 1 (PK) 1-compartment PK model, single i.v.
dose, linear elimination
5 3 (0.60) 20, 50, 200 80, 200, 800 4
Simulation 2 (PD) Emax PD model with baseline 7 3 (0.43) 20, 50, 200 80, 200, 800 4
PK pharmacokinetic, PD pharmacodynamic, i.v. intravenous
a Simulated data (8-fold increase in the number of individuals compared to the original dataset)
J Pharmacokinet Pharmacodyn (2016) 43:597–608 601
123
than their reference, at 11.4 and 16.5 instead of 7 and 10 for
phenobarbital and pefloxacin, respectively (Table 2).
For the simulated datasets of equal size (middle panel of
Fig. 1), bootstrap dOFV distributions also deviated from
the theoretical dOFV distributions, although the extent of
deviation was reduced. The median degrees of freedom
was 8.8 instead of 7 for phenobarbital (i.e. around 26 %
higher) and 11.3 instead of 10 for pefloxacin (i.e. around
13 % higher). Differences in degrees of freedom between
datasets were high, with degrees of freedom spanning
5.5–7.5 df.
For the simulated datasets of eight-time increased size
(right panel of Fig. 1), bootstrap dOFV distributions were
much closer to the theoretical dOFV distributions: the
median degrees of freedom was 7.4 instead of 7 for phe-
nobarbital (i.e. around 6 % higher) and exactly 10 for
pefloxacin (i.e. no increase). Differences in degrees of
freedom between datasets were less marked than with
datasets of equal size, with degrees of freedom spanning
1–2 df.
Simulation examples
As for the real data examples, theoretical and SSE dOFV
distributions were almost superimposed whichever dataset
size (Fig. 2), and bootstrap dOFV distributions showed
different patterns for different dataset sizes. Bootstrap
dOFV distributions behaved similarly for the two simula-
tion examples.
The range of bootstrap dOFV distributions decreased
with increasing dataset size, and approached more and
more the theoretical dOFV distribution. For the smallest
dataset size of 20 patients (left panel of Fig. 2), the mean
bootstrap degrees of freedom was 25 % higher than the
theoretical for the PK example and 20 % higher for the PD
example (Table 2). With 50 patients (middle panel of
Fig. 2), discrepancies were reduced to 10 % increases over
the theoretical for both examples. At the highest sample
size of 200 patients (right panel of Fig. 2), discrepancies
had almost disappeared. As previously observed with the
real data examples, differences in degrees of freedom
between datasets also decreased with increasing dataset
size. Ranges decreased from 6 to 1.5 df in the PK example
and from 8 to 2 df in the PD example, approximately
halving at each dataset size.
For the simulation examples, further properties of the
bootstrap could be investigated as the true uncertainty
distribution could be estimated from the simulations. Fig-
ure 3 displays the 90 % coverage of model parameters for
each dataset size. Trends with increasing dataset size were
similar between the two examples: bootstrap coverage was
always satisfactory for fixed effects, but deviations from
the expected coverage were observed for random effects at
the lowest sample size and to a lesser extent at the middle
sample size. Coverage of IIV and RUV were between 0.70
and 0.80 instead of 0.90 for datasets with 20 patients in
both examples. With 50 patients, coverage increased to
0.85 except for the RUV of the PK example, which peaked
at 0.95. Coverage of all random effects was close to the
expected level with 200 patients.
Figure 4 displays the outer bounds of increasing CI
levels of the IIV parameters of the PD example based on
the bootstrap and on the reference SSE for each dataset
size. Values were normalized by the true simulation value
of each parameter. Discrepancies between the bootstrap
and the reference CI bounds were apparent at low sample
sizes, but disappeared as sample size increased to 50
patients for IIV E0 or to 200 patients for IIV ED50. With
20 patients, bootstrap underestimated the uncertainty of all
IIV parameters. Both bounds were underestimated, mean-
ing that the CI were not only too narrow but also shifted
down. Medians of the bootstrap distributions (i.e. CI = 0)
were 20–25 % lower than the true simulation parameter.
Some downward bias was also observed for the medians of
the SSE. Bootstrap upper bounds were consistently below
the reference bounds, with differences increasing with
increasing CI: the upper bound of the 95 % CI of IIV E0
was 35 % above the simulation value with bootstrap, ver-
sus 70 % with the reference. For IIV ED50, this value was
60 % with bootstrap instead of 120 % with the reference.
Table 2 Degrees of freedom of
the dOFV distributions for the
real data and simulation
examples
Real data examples Df Chi square
(theoretical)




Phenobarbital [11] 7 11.4 8.81 (6.86, 14.3) 7.35 (6.45, 8.45)











Simulation 1 (PK) 5 6.25 (4.32, 10.6) 5.48 (4.10, 7.15) 5.07 (4.42, 5.94)
Simulation 2 (PD) 7 8.39 (5.74, 14.4) 7.55 (6.22, 9.93) 7.15 (6.24, 8.08)
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Lower bounds were also below the reference bounds, but
differences decreased with increasing CI and were less
marked. For IIV E0, the lower bound of the 95 % CI was
60 % below the simulation value with bootstrap, versus
55 % with the reference. For IIV E0, the lower bound of
the bootstrap 90 % CI converged to the lower bound of the
reference, 80 % below the simulation value. With 50
patients, bootstrap and reference CI bounds for IIV E0
overlapped at all CI and medians were at the true simula-
tion value. This was not the case for IIV ED50, which
displayed similar patterns with 50 patients than with 20
patients, even if differences between the bootstrap and the
reference were less marked. With 200 patients, bootstrap
and reference CI bounds overlapped for all CI for both IIV.
Discussion
The dOFV diagnostic enabled to assess whether a given
uncertainty estimate could be considered adequate. When it
was not, i.e. when the dOFV distribution of the bootstrap
was above the theoretical distribution, it translated into
suboptimal coverage of the random effects, for which both
the medians and the CI widths were underestimated.
Fig. 2 dOFV distribution plots
for the two simulation
examples. Grey shaded areas
represent the range of dOFV
curves for n = 100 bootstraps,
with the theoretical dOFV
distribution superimposed (solid
black line). One panel
corresponds to one simulation
example and dataset size. Sim
simulation, pat. patients
Fig. 3 90 % coverage for all
parameters of the two
simulation examples. One panel
corresponds to one simulation
example and dataset size. CL





effect, ED50 dose leading to
half the maximum effect, HILL
Hill factor, Sim simulation, pat.
patients
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Difference of about 1.5 df led to an underestimation of the
90 % coverage by 5–20 %, and to underestimations of
medians and 90 % CI widths by about 20 %. Diagnosing a
priori in which cases bootstrap is inadequate based on
sample size proved inappropriate for NLMEM, as will be
discussed below. An a posteriori method, based on
parameter-specific ‘‘effective’’ sample sizes, will be pro-
posed. In the investigated examples, effective sample sizes
greater than 45 individuals led to good coverage and CI,
and could be used to identify parameters which uncertainty
was not well described by the bootstrap. Depending on the
purpose of the modelling, this could for example be
addressed by using a different uncertainty method less
sensitive to sample size, such as SIR [5].
Development and use of the dOFV distribution
diagnostic
To the authors’ knowledge, this is the only currently
available diagnostic of this kind for NLMEM, and poten-
tially for other types of models as well. The dOFV diag-
nostic is a global test: as the dOFV distributions do not
differentiate between parameters, it does not indicate for
which parameter(s) the uncertainty is not well described.
The diagnostic was exemplified on bootstrap, but it can be
applied to any method for assessing parameter uncertainty,
provided parameter vectors can be drawn from the pro-
posed uncertainty distribution (which is not the case for
likelihood profiling for example). The developed diagnos-
tic is based on evaluating the likelihood of the data at hand
for a number of parameter vectors drawn from the pro-
posed uncertainty. If the proposed uncertainty is the true
uncertainty, differences between these likelihoods and the
likelihood of the final parameter estimates, summarized by
the dOFV distribution, are expected to follow a Chi square
distribution. Given the importance of parameter uncertainty
in decision-making, there is no reason why scrutiny
towards uncertainty estimates should be ignored. Along
with other efforts towards a standardization of model
building and evaluation procedures [16], the dOFV diag-
nostic should be an integral part of model assessment. This
is particularly true as the performance of the different
methods to obtain estimates of parameter uncertainty
remains unclear. The methods themselves are not stan-
dardized: bootstrap for example can be done in many dif-
ferent ways [17], both in the computation of the
bootstrapped datasets (nonparametric and parametrics
methods, stratification strategy) and in the computation of
the resulting uncertainty (for example handling of sam-
ples for which minimization was not successful, bias-cor-
rection [18], Winsorization [19]). Recent work based on
extensive simulations [20, 21] has investigated the per-
formance of the covariance matrix and different bootstrap
methods and provided some guidance towards in which
settings to use which method. However, simulation studies
will never be able to cover the full space of possible
designs, models and methods. A diagnostic for assessing
the appropriateness of a particular method with a particular
model and data is thus greatly needed.
Limitations of the dOFV distribution diagnostic
Two assumptions were made when using the theoretical
distribution as reference distribution in the dOFV
Fig. 4 Comparative CI bounds
between the bootstrap and the
reference (SSE) at different
confidence levels for the IIV
parameters of the second
simulation example. Values
were normalized by the true
simulation value. For the
bootstrap, median values over
all simulation are displayed. IIV
inter-individual variability, E0
baseline, EMAX maximum
effect, ED50 dose leading to
half the maximum effect, CI
confidence level, pat. patients,
obs. observations
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diagnostic: that the dOFV distribution follows a Chi square
distribution at the investigated sample sizes, and that the
degrees of freedom of this distribution corresponds to the
total number of estimated parameters for NLMEM. These
assumptions were tested by computing the SSE dOFV
distributions, which correspond to the empirical dOFV
distributions obtained by fitting the model on data simu-
lated from that model. In all investigated examples, the
SSE dOFV distributions did not differ from the theoretical
dOFV distributions and followed a Chi square distribution
with degrees of freedom equal to the total number of
estimated parameters. This allowed the use of the theo-
retical distribution in the investigated settings. Generaliz-
ing these results, it was expected that the dOFV distribution
would follow a Chi square distribution at commonly used
sample sizes in NLMEM. However, it remains question-
able whether the degrees of freedom would always be
equal to the number of estimated parameters, in particular
under higher nonlinearity or additional parameter con-
straints. In any case, the degrees of freedom can only be at
or below the number of parameters, so any dOFV distri-
bution above the theoretical distribution is known to be a
suboptimal description of parameter uncertainty. If the
dOFV distribution of a proposed uncertainty were to be
below the theoretical, the authors recommend performing
an SSE-type exercise in order to obtain a more precise
estimate of the expected dOFV distribution. No formal test
such as the Kolmogorov–Smirnoff test was performed to
assess whether the dOFV distribution was significantly
different than the theoretical distribution. Such a test was
not considered for two reasons. First, it was uncertain to
which extent the theoretical distribution would correspond
to the true empirical distribution for all NLMEM. Second,
the degrees of freedom was judged to provide more
information on the extent of the inadequacy than a yes/no
answer from a formal hypothesis test.
Bootstrap adequacy in real data examples
In addition to the development of the dOFV diagnostic, this
work also provided insight on the performance of case
bootstrap in a number of scenarios. Bootstrap proved
unsuitable for the real data examples investigated. The
estimated degrees of freedom of the dOFV distributions
were more than 1.5-fold their expected value. The data
contained moderate numbers of individuals (59–74), but
few observations per individual as well as unbalanced
designs. Regarding the models, their structures were simple
(linear processes and well informed covariate relation-
ships) but featured many random effects, especially in the
pefloxacin example. It is important to note that no strati-
fication was performed here. Stratification on the number
of observations per individual could have been beneficial in
both examples, as the number of observations per patient
spanned rather heterogeneous ranges (between 1 and 6 for
phenobarbital and between 3 and 9 for pefloxacin). How-
ever, the number of strata to use would not have been
straightforward and would potentially have led to too small
subgroups. Stratification on other variables such as
covariates included in the model or dose were not con-
sidered here as their distribution was homogenous or
irrelevant. In the pefloxacin example, 5 % of the bootstrap
runs failed and 50 % had one or more unestimable variance
parameters, highlighting further limitations of the bootstrap
when minimization is problematic. The dOFV distribution
using only successful runs without boundary issues differed
from the presented distribution, which included all runs
(data not shown). Excluding problematic runs lead to a
distribution closer to the Chi square distribution, with a
degrees of freedom of 14 instead of 16.5. CI were also
modified, confirming that the way bootstrap runs are han-
dled can influence the results. Lastly, simulations based on
the published models and realized designs were performed
to test the influence of model misspecification in the
observed inadequacy of the bootstrap: inadequacy was still
apparent, but to a lesser extent. These results confirmed
that the performed bootstrap was suboptimal, but showed
that part of the discrepancy seen with the real data was due
to model misspecification.
Bootstrap adequacy in simulation examples
Compared to the real data examples, data in the simulation
examples was richer and more balanced, with the number
of individuals varying from 20 to 200. The PK model was
similar to the real data example, but the PD model, a sig-
moid Emax function, contained more nonlinear parameters.
Both examples showed similar increases in degrees of
freedom at low sample size as the simulations based on the
real data examples, i.e. increases around 25 % over the
expected value. The simulation examples enabled to link
the global adequacy of the uncertainty estimated by the
bootstrap (over all parameters), as measured by changes in
dOFV distribution, to the local adequacy of this uncertainty
(for each parameter separately). The observed inadequacy
of the bootstrap at low sample size could thus be attributed
to a suboptimal estimation of the uncertainty of the random
effects parameters only, as shown by less datasets than
expected including the true simulation value (i.e. subopti-
mal coverage). Focusing on these parameters, it became
apparent that at low sample sizes bootstrap CI around
random effects were decreased as well as shifted down-
wards, underestimating both the actual values of the ran-
dom effect and their uncertainty, especially in the upper
bounds.
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Difficulty of defining sample sizes sufficient
for the bootstrap to be adequate
The performance of case bootstrap is expected to depend
on the number of ‘‘cases’’, i.e. individuals in typical
NLMEM settings, which is why the simulations investi-
gated the impact of increasing number of individuals.
However, the investigated examples highlighted the com-
plexity of defining an appropriate dataset size for bootstrap:
similar changes in degrees of freedom were observed for
datasets with 20 individuals as for datasets with 60–70
individuals. The performance of bootstrap thus does not
only depend on the number of cases. It also depends upon
the homogeneity of the information content between the
cases, or an appropriate stratification strategy under
heterogeneity, so as to preserve the overall information
content of the bootstrapped dataset. However, stratification
decreases the effective sample size and introduces vari-
ability. In addition, the definition of strata may indeed not
be straightforward in many clinical settings where design
parameters are very different between individuals, and may
thus lead to different results under different stratifications.
Another issue for mixed models is that the information
contained in an individual about a parameter does not only
depend on the design, but also on the individual’s param-
eter value. Stratification at the individual parameter level is
however highly problematic. Lastly, the information con-
tent of the data always needs to be related to the size and
complexity of the model. Typically, richer datasets lead to
more complex models and thus the effective information
content may actually be similar between datasets of various
sizes for models of various sizes. In addition, the different
parameters of nonlinear models are not informed equally
by a given design, and thus in theory the adequacy of
uncertainty estimates should be defined at the parameter
level.
Using parameter-specific ‘‘effective’’ sample sizes
to better identify when bootstrap is adequate
Instead of trying to assess the adequacy of bootstrap based
on the number of individuals, one could try to quantify the
information content for each parameter separately, taking
all these factors into account. A possibility for doing so
could be to calculate an effective sample size for each
parameter. The effective sample size represents how many
individuals with perfect information the estimated uncer-
tainty for one parameter corresponds to. Calculating the
effective sample size can be done for fixed and random
effects using the formulas for standard errors of means
(Eq. 4) and variances (Eq. 5). In the simple case of a model
where all fixed effects are associated with one random
effect, the effective sample size N can then be calculated as
follows:
SE Xð Þ ¼ SD Xð Þﬃﬃﬃﬃ
N
p ! N ¼ VAR Xð Þ
VAR Xð Þ ð4Þ
where X is the estimated fixed effect for the population, X
is the vector of the individual parameters, SDðXÞ is the
standard deviation of the individual parameters, N is the
effective sample size.VARðXÞ corresponds to the variance
of the random effect associated with X and SEð XÞ to the
estimate of the standard error of the fixed effect.






¼ 2 VAR Xð Þ




RSE VAR Xð Þð Þ
 2
þ 1 ð5Þ
where VARðXÞ is the estimated random effect variance,
SE VARðXÞð Þ its estimated standard error, N is the effective
sample size, SD Xð Þ is the estimated random effect standard
deviation and RSE VAR Xð Þð Þ is the relative standard error
of VAR Xð Þ.
The effective sample size for fixed effects and inter-in-
dividual variances is expected to be at maximum the total
number of individuals in the dataset. For inter-occasion
variances, the effective sample size is at maximum the total
number of occasions (i.e. the sum of the number of occa-
sions per individual) minus the total number of individuals,
as random effects related to inter-individual variances need
to be differentiated from those related to inter-occasion
variances. Similarly, for residual error variances, N can be
as high as the total number of observations minus the
number of individuals and minus the sum of the number of
occasions per individual. Effective sample sizes were cal-
culated for the real and simulated data examples and are
displayed in Fig. 5. For phenobarbital, the number of indi-
viduals with perfect information was below 6 for CL, V and
IIV CL but at 30 for IIV V. For pefloxacin, the effective
sample size was around 30 for fixed effects, between 15 and
20 for inter-individual variances and very low for IOV V.
The effective sample size for the RUV was close to the total
number of individuals in both real examples. Such low
effective sample sizes support the fact that bootstrap was not
appropriate in these examples. Effective sample sizes with
simulated PK data ranged from 10–15 with 20 patients, to
35–45 with 50 patients and to 110–175 with 200 patients.
They were relatively homogenous between parameters. In
the PD example, effective sample sizes were lower and more
heterogeneous. ED50 presented effective sample sizes close
to 0 due to extreme values in the bootstrap driving the
standard error at low sample sizes to very high values
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[SE(ED50) = 1020 for 20 patients, 40 000 for 50 patients vs.
1 for 200 patients]. Even with 200 patients the effective
sample size was low as the standard error was still much
higher than the IIV. For the remaining parameters, effective
sample sizes were higher: N was close to the total number of
individuals for E0, between half and the total number of
individuals for IIV and less than the number of observations
minus the number of individuals for RUV. If one wants to
establish a cut-off for when the bootstrap is valid, these
results could indicate that the minimum number of effective
individuals needs to be at least 45, which is the maximum N
observed in all examples for which bootstrap was not con-
sidered appropriate (real data and simulations below 200
patients). This is a valuable result, however it is important to
point out that the concept of effective sample size was
developed in an exploratory manner here and thus more
investigations are needed if it is to become an established
diagnostic. For example, the influence of fixed effects not
related to IIV, for which N cannot be calculated, was not
investigated. The correlation of N with shrinkage could be
of interest in order to use shrinkage as an alternative,
potentially more straightforward way to estimate effective
sample sizes. A high correlation between these two metrics,
with high shrinkage corresponding to low N, was observed
in the investigated example, but the establishment of a
quantitative relationship was not attempted. The impact of
covariate effects on the N of corresponding fixed effects
may also need to be investigated: for the phenobarbital
example, N for CL and V increased 6-fold when fixing the
covariate effect instead of estimating it. Lastly, the precision
around the calculated N was not quantified in this work. N
was observed to be sometimes quite variable between sim-
ulated datasets, which may need to be considered if taking
decisions based on the calculated effective sample size.
Conclusion
A diagnostic based on dOFV distributions was developed and
is recommended to be routinely used to assess the appropri-
ateness of a given parameter uncertainty distribution. A
bootstrap dOFV distribution higher than the theoretical dis-
tribution translated into an underestimation of the medians and
the CI widths of the random effects. Case bootstrap proved
unsuitable for datasets for sample sizes up to 70 individuals,
but sample size was not deemed a good predictor of bootstrap
appropriateness. Parameter-specific ‘‘effective’’ sample sizes,
showing good bootstrap results above 45 effective individuals,
could be used instead, but require more investigation.
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